The surprising AIM-HIGH results are not surprising when viewed through a particle lens

Journal of Clinical Lipidology

Volumn 5, Issue 5, 2011, Pages 368-370

  Otvos, James D ^a  

^a LIPOSCIENCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATIN;

CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; PRIORITY JOURNAL; REVIEW; RISK;

EID: 80053893454     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.06.012     Document Type: Editorial

References (13)

1. J.D. Otvos, E.J. Jeyarajah, and W.C. Cromwell Measurement issues related to lipoprotein heterogeneity Am J Cardiol 90 suppl 2002 22i 29i (Pubitemid 35284908)
2. J.D. Otvos, D. Collins, and D.S. Freedman LDL and HDL particle subclasses predict coronary events and are changed favorably by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation 113 2006 1556 1563 (Pubitemid 43739414)
3. W.C. Cromwell, J.D. Otvos, and M.J. Keyes LDL particle number and risk for future cardiovascular disease in the Framingham Offspring Study - implications for LDL management J Clin Lipidol 1 2007 583 592 (Pubitemid 350215511)
4. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 133
5. R.B. Goldberg, D.M. Kendall, and M.A. Deeg A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 18 2005 1547 1554 (Pubitemid 40923063)
6. J. Hsia, J.D. Otvos, and J.E. Rossouw Lipoprotein particle concentrations may explain the absence of coronary protection in the Women's Health Initiative hormone trials Arterioscler Thromb Vasc Biol 28 2008 1666 1671
7. AIM-HIGH investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) Am Heart J 161 2011 471 477
8. H. Jafri, A.A. Alsheikh-Ali, P. Mooney, C.D. Kimmelsteil, R.H. Karas, and J.T. Kuvin Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD J Clin Lipidol 3 2009 45 50
9. S.L. Airan-Javia, R.L. Wolf, M.L. Wolfe, M. Tadesse, E. Mohler, and M.P. Reilly Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy Am Heart J 157 2009 687 688
10. E. Di Angelantonio, N. Sarwar, and P. Perry Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
11. Mackey RH, Greenland P, Goff DC Jr, et al. The relationship of HDL cholesterol and HDL particles to carotid atherosclerosis and incident cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA). AHA Cardiovascular Disease Epidemiology and Prevention Scientific Sessions, March 2011.
12. S. Mora, M. Szklo, and J.D. Otvos LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis Atherosclerosis 192 2007 211 217 (Pubitemid 46602300)
13. K. El Harchaoui, B.J. Arsenault, and R. Franssen High-density lipoprotein particle size and concentration and coronary risk Ann Intern Med 150 2009 84 93